Vanguard Asset Management
MDGL icon

Vanguard Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Vanguard Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16M Buy
15,204
+1,114
+8% +$571K 0.01% 809
2026
Q1 		$7.38M Buy
+14,090
New +$6.73M 0.01% 755

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Asset Management's MDGL Position: Q2 2026 in Review

Vanguard Asset Management increased its Madrigal Pharmaceuticals (MDGL) stake by 7.9% in Q2 2026, buying an estimated $571K and bringing the position to 15,204 shares worth $8.16M. The position accounts for 0.01% of the portfolio, ranked #809.

Vanguard Asset Management first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. 402 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Vanguard Asset Management held 15,204 shares of Madrigal Pharmaceuticals worth $8.16M as of Q2 2026.
  • Vanguard Asset Management bought 1,114 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Madrigal Pharmaceuticals made up 0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #809 holding.
  • Vanguard Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 402 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.